NOUVEAUX DERIVES DE LA TRIAZOLO-QUINAZOLINE, LEUR PREPARATION ET MEDICAMENTS CONTENANT CES

NOUVEAUX DERIVES DE LA TRIAZOLO-QUINAZOLINE, LEUR PREPARATION ET MEDICAMENTS CONTENANT CES

1411767 Triazoloquinazolines SANDOZ Ltd 13 Dec 1972 [17 Dec 1971] 57419/72 Heading C2C Triazoloquinazolines of the general formula wherein one of P and Q is a nitrogen atom and the other is a group in which R 2 is hydrogen atom or a C 1-4 alkyl group, either (a) n is 0, 1, 2 or 3 and R is F, Cl or B...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: G.E. HARDTMANN, F.G. KATHAWALA
Format: Patent
Sprache:fre
Schlagworte:
CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator G.E. HARDTMANN
F.G. KATHAWALA
description 1411767 Triazoloquinazolines SANDOZ Ltd 13 Dec 1972 [17 Dec 1971] 57419/72 Heading C2C Triazoloquinazolines of the general formula wherein one of P and Q is a nitrogen atom and the other is a group in which R 2 is hydrogen atom or a C 1-4 alkyl group, either (a) n is 0, 1, 2 or 3 and R is F, Cl or Br or a C 1-3 alkyl, C 1-3 alkoxy, nitro or trifluoromethyl group, provided that (i) when n is 2 or 3, the radicals R are the same or different, (ii) when n is 2 or 3, each R is other than a nitro or trifluoromethyl group and (iii) when n is 3, each R is a C 1-3 alkoxy group, or (b) n is 2 and the radicals R are located on adjacent carbon atoms and together form a methylenedioxy group and either (c) R 1 is a -OR 3 group in which R 3 is a C 1-6 alkyl, allyl, methylallyl or propargyl group, a -ZNR 4 R 5 group in which Z is a straight or branched chain C 1-4 alkylene group and each of R 4 and R 5 is a C 1-3 alkyl group, or a group of the formula wherein m is 0, 1, 2 or 3 and p is 2, 3, 4 or 5, or (d) R 1 is a -NR 6 R 7 group in which either (e) R 6 is a hydrogen atom and R 7 is a hydrogen atom, a C 1-5 alkyl, C 1-4 alkoxy-C 1-4 alkyl, allyl, methylallyl, propargyl or C 3-6 cycloalkyl group or a -ZNR 4 R 5 group, or (f) R 6 and R 7 , together with the N atom to which they are attached, form a di-C 1-3 alkylamino, diallylamino, di(methylallyl)amino or dipropargyl group or a group of the formula in which X is a direct bond, -CH 2 -, -O- or =NR 8 , in which R 8 is a hydrogen atom or a C 1-3 alkyl group, and x and y are 0 or 1, provided that X is a direct bond when x or y is 0, provided that when Q is a N atom and P is a =CH- group, then R 1 is a -OR 3 group or a -NR 6 1R 7 1 group, in which either R 6 1 is a hydrogen atom and R 7 1 is a C 1-4 alkoxy-C 1-4 alkyl or C 3-6 cycloalkyl group, or R 6 1 and R 7 1, together with the N atom to which they are attached, form a group of the formula VI in which one or both of x and y is 0, and acid addition salts thereof are prepared (A) by reacting a halotriazoloquinazoline of the general formula with a compound of the general formula HNR 6 11R 7 11 to give a triazoloquinazoline of the general formula P11, Q11, R 6 11 and R 7 11 being the same as P,Q, R 6 and R 7 except that when Q11 is N and P11 is =CH-, then R 6 11 and R 7 11 are as R 6 1 and R 7 1 and Y being Cl or Br; (B) by reacting a halotriazoloquinazoline of the general formula with a compound of the general formula MOR 3 11 to give a triazoloquinazoline of the general form
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_BE792856A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>BE792856A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_BE792856A3</originalsourceid><addsrcrecordid>eNqFyrsKwkAQRuE0FqK-gswDmEbxVo6bX1xIZuNmNkiaEGStRAPx_VHB3uo7xRknjbhQg8OFMnhbo_pIOZN6y43LXXoOVr5lBQvKETyVHiV7VuuEoFQgs4YLiFZknCiERcmgmiajW3cf4uznJJkfoeaUxv7ZxqHvrvERX-0B2_1yt97w6u_wBlkeMNU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>NOUVEAUX DERIVES DE LA TRIAZOLO-QUINAZOLINE, LEUR PREPARATION ET MEDICAMENTS CONTENANT CES</title><source>esp@cenet</source><creator>G.E. HARDTMANN ; F.G. KATHAWALA</creator><creatorcontrib>G.E. HARDTMANN ; F.G. KATHAWALA</creatorcontrib><description>1411767 Triazoloquinazolines SANDOZ Ltd 13 Dec 1972 [17 Dec 1971] 57419/72 Heading C2C Triazoloquinazolines of the general formula wherein one of P and Q is a nitrogen atom and the other is a group in which R 2 is hydrogen atom or a C 1-4 alkyl group, either (a) n is 0, 1, 2 or 3 and R is F, Cl or Br or a C 1-3 alkyl, C 1-3 alkoxy, nitro or trifluoromethyl group, provided that (i) when n is 2 or 3, the radicals R are the same or different, (ii) when n is 2 or 3, each R is other than a nitro or trifluoromethyl group and (iii) when n is 3, each R is a C 1-3 alkoxy group, or (b) n is 2 and the radicals R are located on adjacent carbon atoms and together form a methylenedioxy group and either (c) R 1 is a -OR 3 group in which R 3 is a C 1-6 alkyl, allyl, methylallyl or propargyl group, a -ZNR 4 R 5 group in which Z is a straight or branched chain C 1-4 alkylene group and each of R 4 and R 5 is a C 1-3 alkyl group, or a group of the formula wherein m is 0, 1, 2 or 3 and p is 2, 3, 4 or 5, or (d) R 1 is a -NR 6 R 7 group in which either (e) R 6 is a hydrogen atom and R 7 is a hydrogen atom, a C 1-5 alkyl, C 1-4 alkoxy-C 1-4 alkyl, allyl, methylallyl, propargyl or C 3-6 cycloalkyl group or a -ZNR 4 R 5 group, or (f) R 6 and R 7 , together with the N atom to which they are attached, form a di-C 1-3 alkylamino, diallylamino, di(methylallyl)amino or dipropargyl group or a group of the formula in which X is a direct bond, -CH 2 -, -O- or =NR 8 , in which R 8 is a hydrogen atom or a C 1-3 alkyl group, and x and y are 0 or 1, provided that X is a direct bond when x or y is 0, provided that when Q is a N atom and P is a =CH- group, then R 1 is a -OR 3 group or a -NR 6 1R 7 1 group, in which either R 6 1 is a hydrogen atom and R 7 1 is a C 1-4 alkoxy-C 1-4 alkyl or C 3-6 cycloalkyl group, or R 6 1 and R 7 1, together with the N atom to which they are attached, form a group of the formula VI in which one or both of x and y is 0, and acid addition salts thereof are prepared (A) by reacting a halotriazoloquinazoline of the general formula with a compound of the general formula HNR 6 11R 7 11 to give a triazoloquinazoline of the general formula P11, Q11, R 6 11 and R 7 11 being the same as P,Q, R 6 and R 7 except that when Q11 is N and P11 is =CH-, then R 6 11 and R 7 11 are as R 6 1 and R 7 1 and Y being Cl or Br; (B) by reacting a halotriazoloquinazoline of the general formula with a compound of the general formula MOR 3 11 to give a triazoloquinazoline of the general formula wherein either R 2 111 is a C 1-4 alkyl group and R 3 11 is as R 3 or R 2 111 is H and R 3 11 is as R 3 1, and M is H or an equivalent of an alkali or alkaline earth metal cation, the process being effected, when MOR 3 11 is a free alcohol, in the presence of an inert organic base or under anhydrous conditions and in the presence of an inert inorganic base; (c) by reacting a hydrazine of the general formula with a compound of the general formula R 2 1C[O(CH 2 ) 2 CH 3 ] 3 under substantially anhydrous conditions to give a triazoloquinazoline of the general formula wherein either (i) R 2 1 is a C 1-4 alkyl group and R 6 111 and R 7 111 are as R 6 and R 7 or (j) R 2 1 is H and R 6 111 and R 7 111 are as R 6 1 and R 7 1, and z is 0 or 1; (D) by reacting a halotriazoloquinazoline of the general formula with a compound of the general formula MOR 3 to give a triazoloquinazoline of the first general formula above wherein R 1 is -OR 3 , provided that when Q is N in the starting material, the process is effected using a compound MOR 3 in which M is H, in the presence of an inert organic base, under anhydrous conditions and under controlled time and temperature conditions, and that when P is N in the starting material and a compound MOR 3 in which M is H is used, the process is effected in the presence of an inert organic base or under anhydrous conditions and in the presence of an inert inorganic base; or (E) by rearranging a triazoloquinazoline of the first general formula above wherein P is under basic conditions or by heating in the presence of an organic acid or to a temperature above the melting point of the starting material to give a triazoloquinazoline of the first general formula above wherein Q is followed optionally by salification of a resulting free base or conversion of a resulting acid addition salt to the corresponding free base. Triazoloquinazolines of the first general formula above wherein R 1 ,P and Q are replaced by R 1 1, P1 and Q1, respectively, which are as R 1 P and Q except that when P1 is N and Q1 is =CH-, then R 1 1 is -OR 3 1 in which R 3 1 is a group of the Formula IV or -NR 6 R 7 , and acid addition salts thereof are novel. Novel halotriazoloquinazolines of the general formula wherein either P111 is in which R 2 11 is a C 1-4 alkyl group and Q111 is N, or P111 is N and Q111 is are prepared (α) when P111 is by reacting a hydrazine of the general formula with a compound of the general formula R 2 11C[O(CH 2 ) 2 CH 3 ] 3 or (#) when Q111 is by chlorinating or brominating a ketone of the general formula which is prepared by rearranging and hydrolysing a halotriazoloquinazoline of the general Formula VII in which P is 2 - Cyclopropylamino - 4 - hydrazino - 6,7- dimethoxyquinazoline is prepared by reacting 2- chloro - 4 - hydrazino - 6,7 - dimethoxyquinazoline with cyclopropylamine. Pharmaceutical compositions having hypotensive and antiinflammatory activity comprise, as active ingredient, one of the novel triazoloquinazolines or halotriazoloquinazolines as defined above or, where appropriate, a pharmaceutically acceptable acid addition salt thereof, together with a pharmaceutically acceptable diluent or carrier. Reference has been directed by the Comptroller to Specification 1,374,769.</description><language>fre</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; METALLURGY ; ORGANIC CHEMISTRY</subject><creationdate>1973</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=19730615&amp;DB=EPODOC&amp;CC=BE&amp;NR=792856A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,777,882,25545,76296</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=19730615&amp;DB=EPODOC&amp;CC=BE&amp;NR=792856A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>G.E. HARDTMANN</creatorcontrib><creatorcontrib>F.G. KATHAWALA</creatorcontrib><title>NOUVEAUX DERIVES DE LA TRIAZOLO-QUINAZOLINE, LEUR PREPARATION ET MEDICAMENTS CONTENANT CES</title><description>1411767 Triazoloquinazolines SANDOZ Ltd 13 Dec 1972 [17 Dec 1971] 57419/72 Heading C2C Triazoloquinazolines of the general formula wherein one of P and Q is a nitrogen atom and the other is a group in which R 2 is hydrogen atom or a C 1-4 alkyl group, either (a) n is 0, 1, 2 or 3 and R is F, Cl or Br or a C 1-3 alkyl, C 1-3 alkoxy, nitro or trifluoromethyl group, provided that (i) when n is 2 or 3, the radicals R are the same or different, (ii) when n is 2 or 3, each R is other than a nitro or trifluoromethyl group and (iii) when n is 3, each R is a C 1-3 alkoxy group, or (b) n is 2 and the radicals R are located on adjacent carbon atoms and together form a methylenedioxy group and either (c) R 1 is a -OR 3 group in which R 3 is a C 1-6 alkyl, allyl, methylallyl or propargyl group, a -ZNR 4 R 5 group in which Z is a straight or branched chain C 1-4 alkylene group and each of R 4 and R 5 is a C 1-3 alkyl group, or a group of the formula wherein m is 0, 1, 2 or 3 and p is 2, 3, 4 or 5, or (d) R 1 is a -NR 6 R 7 group in which either (e) R 6 is a hydrogen atom and R 7 is a hydrogen atom, a C 1-5 alkyl, C 1-4 alkoxy-C 1-4 alkyl, allyl, methylallyl, propargyl or C 3-6 cycloalkyl group or a -ZNR 4 R 5 group, or (f) R 6 and R 7 , together with the N atom to which they are attached, form a di-C 1-3 alkylamino, diallylamino, di(methylallyl)amino or dipropargyl group or a group of the formula in which X is a direct bond, -CH 2 -, -O- or =NR 8 , in which R 8 is a hydrogen atom or a C 1-3 alkyl group, and x and y are 0 or 1, provided that X is a direct bond when x or y is 0, provided that when Q is a N atom and P is a =CH- group, then R 1 is a -OR 3 group or a -NR 6 1R 7 1 group, in which either R 6 1 is a hydrogen atom and R 7 1 is a C 1-4 alkoxy-C 1-4 alkyl or C 3-6 cycloalkyl group, or R 6 1 and R 7 1, together with the N atom to which they are attached, form a group of the formula VI in which one or both of x and y is 0, and acid addition salts thereof are prepared (A) by reacting a halotriazoloquinazoline of the general formula with a compound of the general formula HNR 6 11R 7 11 to give a triazoloquinazoline of the general formula P11, Q11, R 6 11 and R 7 11 being the same as P,Q, R 6 and R 7 except that when Q11 is N and P11 is =CH-, then R 6 11 and R 7 11 are as R 6 1 and R 7 1 and Y being Cl or Br; (B) by reacting a halotriazoloquinazoline of the general formula with a compound of the general formula MOR 3 11 to give a triazoloquinazoline of the general formula wherein either R 2 111 is a C 1-4 alkyl group and R 3 11 is as R 3 or R 2 111 is H and R 3 11 is as R 3 1, and M is H or an equivalent of an alkali or alkaline earth metal cation, the process being effected, when MOR 3 11 is a free alcohol, in the presence of an inert organic base or under anhydrous conditions and in the presence of an inert inorganic base; (c) by reacting a hydrazine of the general formula with a compound of the general formula R 2 1C[O(CH 2 ) 2 CH 3 ] 3 under substantially anhydrous conditions to give a triazoloquinazoline of the general formula wherein either (i) R 2 1 is a C 1-4 alkyl group and R 6 111 and R 7 111 are as R 6 and R 7 or (j) R 2 1 is H and R 6 111 and R 7 111 are as R 6 1 and R 7 1, and z is 0 or 1; (D) by reacting a halotriazoloquinazoline of the general formula with a compound of the general formula MOR 3 to give a triazoloquinazoline of the first general formula above wherein R 1 is -OR 3 , provided that when Q is N in the starting material, the process is effected using a compound MOR 3 in which M is H, in the presence of an inert organic base, under anhydrous conditions and under controlled time and temperature conditions, and that when P is N in the starting material and a compound MOR 3 in which M is H is used, the process is effected in the presence of an inert organic base or under anhydrous conditions and in the presence of an inert inorganic base; or (E) by rearranging a triazoloquinazoline of the first general formula above wherein P is under basic conditions or by heating in the presence of an organic acid or to a temperature above the melting point of the starting material to give a triazoloquinazoline of the first general formula above wherein Q is followed optionally by salification of a resulting free base or conversion of a resulting acid addition salt to the corresponding free base. Triazoloquinazolines of the first general formula above wherein R 1 ,P and Q are replaced by R 1 1, P1 and Q1, respectively, which are as R 1 P and Q except that when P1 is N and Q1 is =CH-, then R 1 1 is -OR 3 1 in which R 3 1 is a group of the Formula IV or -NR 6 R 7 , and acid addition salts thereof are novel. Novel halotriazoloquinazolines of the general formula wherein either P111 is in which R 2 11 is a C 1-4 alkyl group and Q111 is N, or P111 is N and Q111 is are prepared (α) when P111 is by reacting a hydrazine of the general formula with a compound of the general formula R 2 11C[O(CH 2 ) 2 CH 3 ] 3 or (#) when Q111 is by chlorinating or brominating a ketone of the general formula which is prepared by rearranging and hydrolysing a halotriazoloquinazoline of the general Formula VII in which P is 2 - Cyclopropylamino - 4 - hydrazino - 6,7- dimethoxyquinazoline is prepared by reacting 2- chloro - 4 - hydrazino - 6,7 - dimethoxyquinazoline with cyclopropylamine. Pharmaceutical compositions having hypotensive and antiinflammatory activity comprise, as active ingredient, one of the novel triazoloquinazolines or halotriazoloquinazolines as defined above or, where appropriate, a pharmaceutically acceptable acid addition salt thereof, together with a pharmaceutically acceptable diluent or carrier. Reference has been directed by the Comptroller to Specification 1,374,769.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>1973</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqFyrsKwkAQRuE0FqK-gswDmEbxVo6bX1xIZuNmNkiaEGStRAPx_VHB3uo7xRknjbhQg8OFMnhbo_pIOZN6y43LXXoOVr5lBQvKETyVHiV7VuuEoFQgs4YLiFZknCiERcmgmiajW3cf4uznJJkfoeaUxv7ZxqHvrvERX-0B2_1yt97w6u_wBlkeMNU</recordid><startdate>19730615</startdate><enddate>19730615</enddate><creator>G.E. HARDTMANN</creator><creator>F.G. KATHAWALA</creator><scope>EVB</scope></search><sort><creationdate>19730615</creationdate><title>NOUVEAUX DERIVES DE LA TRIAZOLO-QUINAZOLINE, LEUR PREPARATION ET MEDICAMENTS CONTENANT CES</title><author>G.E. HARDTMANN ; F.G. KATHAWALA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_BE792856A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>fre</language><creationdate>1973</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><toplevel>online_resources</toplevel><creatorcontrib>G.E. HARDTMANN</creatorcontrib><creatorcontrib>F.G. KATHAWALA</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>G.E. HARDTMANN</au><au>F.G. KATHAWALA</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>NOUVEAUX DERIVES DE LA TRIAZOLO-QUINAZOLINE, LEUR PREPARATION ET MEDICAMENTS CONTENANT CES</title><date>1973-06-15</date><risdate>1973</risdate><abstract>1411767 Triazoloquinazolines SANDOZ Ltd 13 Dec 1972 [17 Dec 1971] 57419/72 Heading C2C Triazoloquinazolines of the general formula wherein one of P and Q is a nitrogen atom and the other is a group in which R 2 is hydrogen atom or a C 1-4 alkyl group, either (a) n is 0, 1, 2 or 3 and R is F, Cl or Br or a C 1-3 alkyl, C 1-3 alkoxy, nitro or trifluoromethyl group, provided that (i) when n is 2 or 3, the radicals R are the same or different, (ii) when n is 2 or 3, each R is other than a nitro or trifluoromethyl group and (iii) when n is 3, each R is a C 1-3 alkoxy group, or (b) n is 2 and the radicals R are located on adjacent carbon atoms and together form a methylenedioxy group and either (c) R 1 is a -OR 3 group in which R 3 is a C 1-6 alkyl, allyl, methylallyl or propargyl group, a -ZNR 4 R 5 group in which Z is a straight or branched chain C 1-4 alkylene group and each of R 4 and R 5 is a C 1-3 alkyl group, or a group of the formula wherein m is 0, 1, 2 or 3 and p is 2, 3, 4 or 5, or (d) R 1 is a -NR 6 R 7 group in which either (e) R 6 is a hydrogen atom and R 7 is a hydrogen atom, a C 1-5 alkyl, C 1-4 alkoxy-C 1-4 alkyl, allyl, methylallyl, propargyl or C 3-6 cycloalkyl group or a -ZNR 4 R 5 group, or (f) R 6 and R 7 , together with the N atom to which they are attached, form a di-C 1-3 alkylamino, diallylamino, di(methylallyl)amino or dipropargyl group or a group of the formula in which X is a direct bond, -CH 2 -, -O- or =NR 8 , in which R 8 is a hydrogen atom or a C 1-3 alkyl group, and x and y are 0 or 1, provided that X is a direct bond when x or y is 0, provided that when Q is a N atom and P is a =CH- group, then R 1 is a -OR 3 group or a -NR 6 1R 7 1 group, in which either R 6 1 is a hydrogen atom and R 7 1 is a C 1-4 alkoxy-C 1-4 alkyl or C 3-6 cycloalkyl group, or R 6 1 and R 7 1, together with the N atom to which they are attached, form a group of the formula VI in which one or both of x and y is 0, and acid addition salts thereof are prepared (A) by reacting a halotriazoloquinazoline of the general formula with a compound of the general formula HNR 6 11R 7 11 to give a triazoloquinazoline of the general formula P11, Q11, R 6 11 and R 7 11 being the same as P,Q, R 6 and R 7 except that when Q11 is N and P11 is =CH-, then R 6 11 and R 7 11 are as R 6 1 and R 7 1 and Y being Cl or Br; (B) by reacting a halotriazoloquinazoline of the general formula with a compound of the general formula MOR 3 11 to give a triazoloquinazoline of the general formula wherein either R 2 111 is a C 1-4 alkyl group and R 3 11 is as R 3 or R 2 111 is H and R 3 11 is as R 3 1, and M is H or an equivalent of an alkali or alkaline earth metal cation, the process being effected, when MOR 3 11 is a free alcohol, in the presence of an inert organic base or under anhydrous conditions and in the presence of an inert inorganic base; (c) by reacting a hydrazine of the general formula with a compound of the general formula R 2 1C[O(CH 2 ) 2 CH 3 ] 3 under substantially anhydrous conditions to give a triazoloquinazoline of the general formula wherein either (i) R 2 1 is a C 1-4 alkyl group and R 6 111 and R 7 111 are as R 6 and R 7 or (j) R 2 1 is H and R 6 111 and R 7 111 are as R 6 1 and R 7 1, and z is 0 or 1; (D) by reacting a halotriazoloquinazoline of the general formula with a compound of the general formula MOR 3 to give a triazoloquinazoline of the first general formula above wherein R 1 is -OR 3 , provided that when Q is N in the starting material, the process is effected using a compound MOR 3 in which M is H, in the presence of an inert organic base, under anhydrous conditions and under controlled time and temperature conditions, and that when P is N in the starting material and a compound MOR 3 in which M is H is used, the process is effected in the presence of an inert organic base or under anhydrous conditions and in the presence of an inert inorganic base; or (E) by rearranging a triazoloquinazoline of the first general formula above wherein P is under basic conditions or by heating in the presence of an organic acid or to a temperature above the melting point of the starting material to give a triazoloquinazoline of the first general formula above wherein Q is followed optionally by salification of a resulting free base or conversion of a resulting acid addition salt to the corresponding free base. Triazoloquinazolines of the first general formula above wherein R 1 ,P and Q are replaced by R 1 1, P1 and Q1, respectively, which are as R 1 P and Q except that when P1 is N and Q1 is =CH-, then R 1 1 is -OR 3 1 in which R 3 1 is a group of the Formula IV or -NR 6 R 7 , and acid addition salts thereof are novel. Novel halotriazoloquinazolines of the general formula wherein either P111 is in which R 2 11 is a C 1-4 alkyl group and Q111 is N, or P111 is N and Q111 is are prepared (α) when P111 is by reacting a hydrazine of the general formula with a compound of the general formula R 2 11C[O(CH 2 ) 2 CH 3 ] 3 or (#) when Q111 is by chlorinating or brominating a ketone of the general formula which is prepared by rearranging and hydrolysing a halotriazoloquinazoline of the general Formula VII in which P is 2 - Cyclopropylamino - 4 - hydrazino - 6,7- dimethoxyquinazoline is prepared by reacting 2- chloro - 4 - hydrazino - 6,7 - dimethoxyquinazoline with cyclopropylamine. Pharmaceutical compositions having hypotensive and antiinflammatory activity comprise, as active ingredient, one of the novel triazoloquinazolines or halotriazoloquinazolines as defined above or, where appropriate, a pharmaceutically acceptable acid addition salt thereof, together with a pharmaceutically acceptable diluent or carrier. Reference has been directed by the Comptroller to Specification 1,374,769.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language fre
recordid cdi_epo_espacenet_BE792856A
source esp@cenet
subjects CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
title NOUVEAUX DERIVES DE LA TRIAZOLO-QUINAZOLINE, LEUR PREPARATION ET MEDICAMENTS CONTENANT CES
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T17%3A52%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=G.E.%20HARDTMANN&rft.date=1973-06-15&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EBE792856A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true